Rare Cancers Europe is a partnership between many organisations.
Rare Cancers Europe is a joint initiative based on a partnership between the European Society for Medical Oncology (ESMO), the European Organisation for Rare Diseases (EURORDIS), the European Cancer Patient Coalition (ECPC), the European Organisation for Research and Treatment of Cancer (EORTC), Conticanet, EuroBoNeT, the World Sarcoma Network (WSN), the Association of European Cancer Leagues (ECL), the Chronic Myeloid Leukaemia Support Group, the International Brain Tumour Alliance (IBTA), Orphanet, the Chronic Myeloid Leukaemia Advocates Network, the Sarcoma Patients EuroNet Association (SPAEN), GIST Support UK & PAWS-GIST, Cancer 52, the Rarer Cancers Foundation (RCF), the International Kidney Cancer Coalition (IKCC), the Chordoma Foundation, the Fondazione IRCCS Istituto Nazionale dei Tumori, the European Institute of Oncology (IEO), the European Society for Paediatric Oncology (SIOP Europe), the European Society of Surgical Oncology (ESSO), the Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI), the European School of Oncology (ESO), the European Oncology Nursing Society (EONS), ecancer, the European Society of Pathology (ESP), the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB), Bristol-Myers Squibb (industry partner), Novartis Oncology (initiating sponsor and industry partner), Lilly (gold industry supporter). The campaign is moreover supported by additional corporate supporters.
The collaboration began in 2008 in relation to the organisation of the conference "Rare Tumours in Europe: Challenges and Solutions". Since then, the organisations have continued to work together and more organisations have joined.